Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem Inc (ENZ) delivers essential tools for molecular diagnostics and biomedical research through its innovative platforms. This news hub provides investors and researchers with timely updates on the company’s developments in life sciences, financial performance, and strategic initiatives.
Access comprehensive coverage of ENZ’s press releases including earnings reports, regulatory milestones, product launches, and partnership announcements. Our curated collection ensures you stay informed about advancements in antibody development, genomic analysis technologies, and clinical laboratory solutions.
Key updates feature progress in translational research applications, intellectual property developments, and global distribution network expansions. All content is verified for accuracy and relevance to support informed decision-making in the bioscience sector.
Bookmark this page for direct access to ENZ’s latest innovations in diagnostic reagents, detection systems, and research methodologies that power modern healthcare discoveries.
Enzo Biochem (NYSE:ENZ) will announce its second quarter 2022 financial results on March 14, 2022, after the market closes. Following the announcement, a live audio webcast and conference call will take place at 4:30 PM ET. Interested parties can join the call by dialing the provided numbers. Enzo Biochem is a leading company in molecular diagnostics with a strong intellectual property portfolio and innovative diagnostic technologies aimed at transforming healthcare. For further details, visit Enzo's official website.
Enzo Biochem, a key player in biosciences, has appointed Hamid Erfanian and Bradley Radoff to its Board of Directors, effective immediately. Directors Dov Perlysky and Rebecca Fischer have stepped down to facilitate this transition. Dr. Mary Tagliaferri will serve as the lead independent director. Both new appointees have extensive backgrounds in diagnostics and corporate governance. Radoff mentioned a mutual agreement with Enzo to enhance shareholder value. Their election is set for the upcoming Annual Meeting, where a Board declassification proposal will also be discussed.
Enzo Biochem reported Q1 FY 2022 revenues of $26.5 million, a 7% sequential increase from $24.8 million in Q4 FY 2021 but a $2.1 million drop year-over-year. The company appointed Hamid Erfanian as CEO, aiming to enhance commercialization strategies. The Enzo Clinical Lab revenue increased by 17% sequentially to $19.7 million, despite a $1.5 million decrease compared to the prior year. Enzo Life Sciences revenue fell by 9% to $6.8 million. A net loss of $2.3 million was reported, with cash and securities totaling $36.9 million.
Enzo Biochem, Inc. (NYSE:ENZ) announced it will release its financial results for the first quarter of 2022 on December 15, 2021, after market close. Following this, a live audio webcast and conference call are scheduled at 4:30 pm ET. The company continues to innovate in molecular diagnostics, leveraging its intellectual property portfolio to meet healthcare needs. For more information, the press release provides a registration link for the conference call, encouraging stakeholders to join and learn about the company's performance and outlook.
Enzo Biochem, a biosciences and diagnostics company, announced that it has granted equity awards to Hamid Erfanian, its new CEO, to secure his employment. The awards include 260,000 restricted stock units (RSUs) and options for 700,000 shares, with a vesting period of three years. This decision aligns with the company's strategy to foster alignment between Erfanian and shareholders' interests. The company will file a Form S-8 to cover these equity awards, and the transaction complies with NYSE regulations.
Bradley L. Radoff, a major shareholder of Enzo Biochem (NYSE: ENZ), has expressed disappointment with the company's independent directors' inadequate response to his concerns regarding corporate governance and long-term performance. Radoff's letter criticizes the Board's lack of engagement and transparency, particularly regarding a new CEO search and addressing shareholder unrest. He accuses the directors of ignoring fiduciary duties and of conducting a sham process for electing new board members. Radoff plans to proceed with an election contest to address these governance issues.
Enzo Biochem has expanded its GoTestMeNow™ online portal, allowing direct access to physician-authorized testing for sexually transmitted infections (STIs). This move addresses privacy concerns and improves convenience, as patients can now order tests online without needing to visit a doctor’s office. The CDC reports approximately 20 million new STI cases annually in the U.S., with significant increases in recent years. The updated service is part of Enzo's strategy to enhance testing accessibility, previously demonstrated through COVID-19 testing.
Enzo Biochem, Inc. (NYSE:ENZ) has appointed Hamid Erfanian as its new Chief Executive Officer, effective early November 2021. Dr. Elazar Rabbani, remaining Chairperson of the Board, will also serve as Chief Scientific Officer. Erfanian, a healthcare executive with over 28 years of experience, previously grew sales significantly at EUROIMMUN. He aims to enhance Enzo's GENFLEX® platform and expand product offerings in diagnostics. The Board expresses confidence in Erfanian's ability to drive growth through innovative platforms and a strong patent base.
Enzo Biochem reported FY 2021 revenues of $117.7 million, marking a 55% increase YoY, with a 4Q revenue of $24.8 million (up 27% YoY). The company achieved an EPS of $0.16, recovering from a loss of $(0.60) the previous year. Key developments include an expanded FDA Emergency Use Authorization for SARS-CoV-2 testing, enhancing its extraction process. The GoTestMeNow service is set to provide direct-to-consumer STI testing. Cost-saving initiatives yielded $10 million in savings, while net income reached $7.9 million. Earnings growth reflects strategic alignment and operational efficiency.
Enzo Biochem (NYSE:ENZ) is set to announce its fourth quarter and fiscal year 2021 financial results on October 12, 2021, before the market opens. Following the announcement, there will be a live audio webcast and conference call at 8:30 am ET. Enzo is known for its innovations in molecular diagnostics and has a significant intellectual property portfolio. The company aims to address the evolving demands of the healthcare sector, though specifics regarding financial performance remain undisclosed in the release.
